Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $109699.0.

  • Cumberland Pharmaceuticals' Interest Expenses fell 2014.57% to $109699.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $606309.0, marking a year-over-year increase of 806.9%. This contributed to the annual value of $605508.0 for FY2024, which is 933.62% down from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Interest Expenses stood at $109699.0 for Q3 2025, which was down 2014.57% from $109547.0 recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year Interest Expenses high stood at $223261.0 for Q4 2024, and its period low was $20021.0 during Q3 2021.
  • Moreover, its 5-year median value for Interest Expenses was $126347.0 (2024), whereas its average is $123181.2.
  • Its Interest Expenses has fluctuated over the past 5 years, first crashed by 7835.25% in 2021, then surged by 64591.68% in 2022.
  • Cumberland Pharmaceuticals' Interest Expenses (Quarter) stood at $27734.0 in 2021, then skyrocketed by 547.06% to $179456.0 in 2022, then decreased by 0.37% to $178792.0 in 2023, then increased by 24.87% to $223261.0 in 2024, then crashed by 50.87% to $109699.0 in 2025.
  • Its Interest Expenses was $109699.0 in Q3 2025, compared to $109547.0 in Q2 2025 and $163802.0 in Q1 2025.